25243-95-2
25243-95-2
Chemical Structure
L-Octanoylcarnitine
- CAS No.: 25243-95-2
- Formula:C15H29NO4
- Molecular Weight:287.40
IUPAC Name: (R)-3-(octanoyloxy)-4-(trimethylammonio)butanoate
InChIKey: CXTATJFJDMJMIY-CYBMUJFWSA-N
SMILES: CCCCCCCC(O[C@H](CC([O-])=O)C[N+](C)(C)C)=O
Biological Activity: L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L-Octanoylcarnitine | 98.0% | L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine (Standard) | ≥98% | L-Octanoylcarnitine (Standard) is the analytical standard of L-Octanoylcarnitine. This product is intended for research and analytical applications. L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine-d3 | L-Octanoylcarnitine-d3 is the deuterium-labeled L-Octanoylcarnitine (HY-113161). L-Octanoylcarnitine-d3 is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine-d3 can be used for the research of breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine-d9 | 99.9% | L-Octanoylcarnitine-d9 is deuterium labeled L-Octanoylcarnitine. L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer.. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Octanoylcarnitine chloride | 99.96% | Octanoylcarnitine chloride is an orally active medium-chain acylcarnitine transport intermediate in fatty acid β-oxidation. Octanoylcarnitine chloride is converted to octanoyl-CoA by carnitine acetyltransferase (CrAT), which then generates energy via β-oxidation in mitochondria of the heart and skeletal muscle. Octanoylcarnitine chloride enhances grip strength and treadmill endurance, alleviates lactic acidosis, distributes in muscle and heart tissues, increases free carnitine levels, and mitigates mitochondrial stress. Octanoylcarnitine chloride is associated with long-chain fatty acid metabolism, shows a positive correlation with subcutaneous fat area in patients with metastatic pancreatic ductal adenocarcinoma, and is closely related to central retinal artery occlusion (CRAO). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Decanoylcarnitine | 99.72% | Decanoylcarnitine is a fatty ester lipid and an acylcarnitine derivative, which is a metabolite associated with impaired fatty acid metabolism in the elderly population. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Hexanoylcarnitine | 99.87% | L-Hexanoylcarnitine is an acylcarnitine and is found to be associated with celiac disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Hexanoylcarnitine | 99.83% | (±)-Hexanoylcarnitine exists in human urine and plasma. (±)-Hexanoylcarnitine can be used as a plasma detection indicator in patients with methylmalonic aciduria, propionic acidemia, and medium-chain acyl-CoA dehydrogenase deficiency. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Decanoyl-L-carnitine (Standard) | ≥98% | Decanoyl-L-carnitine ((-)-Decanoylcarnitine) (Standard) is the analytical standard of Decanoyl-L-carnitine (HY-135035). This product is intended for research and analytical applications. Decanoyl-L-carnitine is an endogenous metabolite. Decanoyl-L-carnitine can be used as a serum metabolic biomarkers as indicators in the progression of intravenous leiomyomatosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Octanoylcarnitine | Octanoylcarnitine is an orally active medium-chain acylcarnitine transport intermediate in fatty acid β-oxidation. Octanoylcarnitine is converted to octanoyl-CoA by carnitine acetyltransferase (CrAT), which then generates energy via β-oxidation in mitochondria of the heart and skeletal muscle. Octanoylcarnitine enhances grip strength and treadmill endurance, alleviates lactic acidosis, distributes in muscle and heart tissues, increases free carnitine levels, and mitigates mitochondrial stress. Octanoylcarnitine is associated with long-chain fatty acid metabolism, shows a positive correlation with subcutaneous fat area in patients with metastatic pancreatic ductal adenocarcinoma, and is closely related to central retinal artery occlusion (CRAO). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(+)-Decanoylcarnitine | (+)-Decanoylcarnitine is an (S)-acylcarnitine derivative and a potent inhibitor of carnitine-acylcarnitine translocase, with an IC50 of 5 μM. (+)-Decanoylcarnitine acts as a competitive inhibitor of long-chain acylcarnitine transferase and (-)-carnitine palmityltransferase. (+)-Decanoylcarnitine blocks hepatic fatty acid oxidation, ketogenesis, oleate-induced activation of gluconeogenesis, as well as associated changes in acetyl-CoA, citrate, redox pair ratios, flavins and pyridine nucleotides. (+)-Decanoylcarnitine reverses ketosis in vivo, enhances insulin-mediated hypoglycemic effects in anesthetized animals, and reduces plasma ketone body levels when used in combination with insulin. (+)-Decanoylcarnitine can be used in studies related to diabetic ketoacidosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Heptanoyl-L-carnitine | Heptanoyl-L-carnitine is an ester product. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nonanoylcarnitine | 99.94% | Nonanoylcarnitine is a metabolite associated with chronic environmental exposure to polycyclic aromatic hydrocarbons (PAH) and fragmented QRS waves in acute myocardial infarction. Nonanoylcarnitine can be used as a potential biomarker for the metabolic outcome of PAH exposure and the prognosis of acute myocardial infarction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine hydrochloride | 99.62% | L-Octanoylcarnitine hydrochloride is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine hydrochloride can be used for the research of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kim M, et al. Association between arterial stiffness and serum L-octanoylcarnitine and lactosylceramide in overweight middle-aged subjects: 3-year follow-up study. PLoS One. 2015 Mar 17;10(3):e0119519. [Content Brief]
- [2]. Schönfeld P, Reiser G. Inhibition of β-oxidation is not a valid therapeutic tool for reducing oxidative stress in conditions of neurodegeneration. J Cereb Blood Flow Metab. 2017 Mar;37(3):848-854. [Content Brief]
- [3]. Hanna Kosnik, et al. CHRONIC HIGH FAT DIET IMPAIRS DETRUSOR MITOCHONDRIAL FATTY ACID OXIDATION IN MALE BUT NOT FEMALE MICE. Journal of UrologyBladder & Urethra: Anatomy, Physiology & Pharmacology I (MP11)1 Apr 2019.
